利用真实世界的数据,开发并验证用于确定多发性骨髓瘤治疗方案的算法。

IF 3 4区 医学 Q2 ONCOLOGY
Future oncology Pub Date : 2024-05-01 Epub Date: 2024-01-17 DOI:10.2217/fon-2023-0696
Sikander Ailawadhi, Dorothy Romanus, Surbhi Shah, Kathy Fraeman, Delphine Saragoussi, Rebecca Morris Buus, Binh Nguyen, Dasha Cherepanov, Lois Lamerato, Ariel Berger
{"title":"利用真实世界的数据,开发并验证用于确定多发性骨髓瘤治疗方案的算法。","authors":"Sikander Ailawadhi, Dorothy Romanus, Surbhi Shah, Kathy Fraeman, Delphine Saragoussi, Rebecca Morris Buus, Binh Nguyen, Dasha Cherepanov, Lois Lamerato, Ariel Berger","doi":"10.2217/fon-2023-0696","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> To validate algorithms based on electronic health data to identify composition of lines of therapy (LOT) in multiple myeloma (MM). <b>Materials & methods:</b> This study used available electronic health data for selected adults within Henry Ford Health (Michigan, USA) newly diagnosed with MM in 2006-2017. Algorithm performance in this population was verified via chart review. As with prior oncology studies, good performance was defined as positive predictive value (PPV) ≥75%. <b>Results:</b> Accuracy for identifying LOT1 (N = 133) was 85.0%. For the most frequent regimens, accuracy was 92.5-97.7%, PPV 80.6-93.8%, sensitivity 88.2-89.3% and specificity 94.3-99.1%. Algorithm performance decreased in subsequent LOTs, with decreasing sample sizes. Only 19.5% of patients received maintenance therapy during LOT1. Accuracy for identifying maintenance therapy was 85.7%; PPV for the most common maintenance therapy was 73.3%. <b>Conclusion:</b> Algorithms performed well in identifying LOT1 - especially more commonly used regimens - and slightly less well in identifying maintenance therapy therein.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"981-995"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data.\",\"authors\":\"Sikander Ailawadhi, Dorothy Romanus, Surbhi Shah, Kathy Fraeman, Delphine Saragoussi, Rebecca Morris Buus, Binh Nguyen, Dasha Cherepanov, Lois Lamerato, Ariel Berger\",\"doi\":\"10.2217/fon-2023-0696\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> To validate algorithms based on electronic health data to identify composition of lines of therapy (LOT) in multiple myeloma (MM). <b>Materials & methods:</b> This study used available electronic health data for selected adults within Henry Ford Health (Michigan, USA) newly diagnosed with MM in 2006-2017. Algorithm performance in this population was verified via chart review. As with prior oncology studies, good performance was defined as positive predictive value (PPV) ≥75%. <b>Results:</b> Accuracy for identifying LOT1 (N = 133) was 85.0%. For the most frequent regimens, accuracy was 92.5-97.7%, PPV 80.6-93.8%, sensitivity 88.2-89.3% and specificity 94.3-99.1%. Algorithm performance decreased in subsequent LOTs, with decreasing sample sizes. Only 19.5% of patients received maintenance therapy during LOT1. Accuracy for identifying maintenance therapy was 85.7%; PPV for the most common maintenance therapy was 73.3%. <b>Conclusion:</b> Algorithms performed well in identifying LOT1 - especially more commonly used regimens - and slightly less well in identifying maintenance therapy therein.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"981-995\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/fon-2023-0696\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/fon-2023-0696","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:验证基于电子健康数据的算法,以确定多发性骨髓瘤(MM)治疗方案(LOT)的组成。材料与方法:本研究使用了亨利福特健康公司(美国密歇根州)2006-2017年新诊断为多发性骨髓瘤的部分成人的电子健康数据。通过病历审查验证了该人群的算法性能。与之前的肿瘤学研究一样,阳性预测值 (PPV) ≥ 75% 即为良好。结果识别 LOT1(N = 133)的准确率为 85.0%。对于最常见的治疗方案,准确率为 92.5%-97.7%,PPV 为 80.6%-93.8%,灵敏度为 88.2%-89.3%,特异性为 94.3%-99.1%。随着样本量的减少,算法性能在随后的LOT中有所下降。在LOT1期间,只有19.5%的患者接受了维持治疗。识别维持疗法的准确率为 85.7%;最常见维持疗法的 PPV 为 73.3%。结论:算法在识别 LOT1(尤其是更常用的治疗方案)方面表现良好,但在识别其中的维持治疗方面表现稍差。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data.

Aim: To validate algorithms based on electronic health data to identify composition of lines of therapy (LOT) in multiple myeloma (MM). Materials & methods: This study used available electronic health data for selected adults within Henry Ford Health (Michigan, USA) newly diagnosed with MM in 2006-2017. Algorithm performance in this population was verified via chart review. As with prior oncology studies, good performance was defined as positive predictive value (PPV) ≥75%. Results: Accuracy for identifying LOT1 (N = 133) was 85.0%. For the most frequent regimens, accuracy was 92.5-97.7%, PPV 80.6-93.8%, sensitivity 88.2-89.3% and specificity 94.3-99.1%. Algorithm performance decreased in subsequent LOTs, with decreasing sample sizes. Only 19.5% of patients received maintenance therapy during LOT1. Accuracy for identifying maintenance therapy was 85.7%; PPV for the most common maintenance therapy was 73.3%. Conclusion: Algorithms performed well in identifying LOT1 - especially more commonly used regimens - and slightly less well in identifying maintenance therapy therein.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信